Johnson & Johnson (NYSE:JNJ) said it has completed its acquisition of Halda Therapeutics OpCo in an all-cash transaction valued at $3.05 billion, strengthening the company’s oncology pipeline with a novel targeted-therapy platform.
The acquisition brings Halda’s proprietary Regulated Induced Proximity Targeting Chimera, or RIPTAC™, technology into Johnson & Johnson’s Innovative Medicine portfolio.
The platform is designed to enable oral, targeted therapies for multiple solid tumors, including prostate cancer, by inducing precision cancer cell killing and potentially overcoming treatment resistance.
Through the deal, Johnson & Johnson adds HLD-0915, a once-daily oral therapy for prostate cancer that is currently in clinical development.
The company said the candidate builds on nearly two decades of innovation in prostate cancer and complements its existing oncology portfolio.
The transaction also includes several earlier-stage RIPTAC™-based programs targeting breast, lung, and other tumor types, as well as potential applications beyond oncology.
Johnson & Johnson said the acquisition will be accounted for as a business combination.
With the transaction closing in 2025, the company expects earnings dilution in the fourth quarter of 2025 and in 2026.
Total dilution to adjusted earnings per share is expected to be about $0.20, split evenly between the two years, reflecting non-recurring charges related to Halda employee equity awards, financing, and integration costs.